{"filing":{"accession_number":"0001628280-26-061558","cik":"0001516551","ticker":"SKYE","company_name":"Skye Bioscience, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-08","primary_document":"skye-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026061558/skye-20260908.htm"},"events":[{"id":32939,"run_id":30282,"accession_number":"0001628280-26-061558","anchor_item_number":"1.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, effective September 8, 2026. The resignation triggered termination of the Master Services Agreement with Lohman \u0026 Associates.","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36236,"accession_number":"0001628280-26-061558","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer, which is a material executive departure. While Item 1.02 formally addresses termination of the Master Services Agreement with Lohman \u0026 Associates, the substantive event triggering the disclosure is Sharp's resignation as CFO. The termination of the service agreement is secondary and directly caused by the CFO departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36237,"accession_number":"0001628280-26-061558","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of CFO John P. Sharp and the appointment of Punit Dhillon as principal financial and accounting officer. While both events are disclosed, the principal action emphasized is the appointment of Dhillon to the CFO role effective September 8, 2026. The appointment of an existing executive (the CEO) to an additional critical financial reporting function is material to investors assessing the company's financial governance and controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32940,"run_id":30282,"accession_number":"0001628280-26-061558","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Skye Bioscience entered into a Transaction Agreement dated August 14, 2026 to acquire Redx Pharma Limited. The company plans to file a proxy statement and seek stockholder approval for the proposed acquisition, which remains subject to customary closing conditions and regulatory approvals.","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36238,"accession_number":"0001628280-26-061558","item_number":"8.01","item_title":"Other Matters.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure centers on a proposed acquisition of Redx Pharma Limited by Skye Bioscience, with a Transaction Agreement dated August 14, 2026. While the section also mentions Nasdaq compliance restoration (a routine administrative matter), the substantive disclosure concerns the pending M\u0026A transaction, including proxy filing plans, stockholder approval requirements, and forward-looking statements about transaction closing conditions and risks. This is a material acquisition activity requiring investor disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36236,"accession_number":"0001628280-26-061558","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer, which is a material executive departure. While Item 1.02 formally addresses termination of the Master Services Agreement with Lohman \u0026 Associates, the substantive event triggering the disclosure is Sharp's resignation as CFO. The termination of the service agreement is secondary and directly caused by the CFO departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-09-11"},{"id":36237,"accession_number":"0001628280-26-061558","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of CFO John P. Sharp and the appointment of Punit Dhillon as principal financial and accounting officer. While both events are disclosed, the principal action emphasized is the appointment of Dhillon to the CFO role effective September 8, 2026. The appointment of an existing executive (the CEO) to an additional critical financial reporting function is material to investors assessing the company's financial governance and controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-09-11"},{"id":36238,"accession_number":"0001628280-26-061558","item_number":"8.01","item_title":"Other Matters.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure centers on a proposed acquisition of Redx Pharma Limited by Skye Bioscience, with a Transaction Agreement dated August 14, 2026. While the section also mentions Nasdaq compliance restoration (a routine administrative matter), the substantive disclosure concerns the pending M\u0026A transaction, including proxy filing plans, stockholder approval requirements, and forward-looking statements about transaction closing conditions and risks. This is a material acquisition activity requiring investor disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:14:48.618634+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-09-11"}]}